The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a development that bolsters its autoimmune portfolio, AbbVie announced that the CHMP has adopted a positive opinion recommending approval of upadacitinib (RINVOQ) for the treatment of adults and adolescents with severe alopecia areata, according to an official statement. The opinion was based on data from the Phase 3 UP-AA clinical program, which showed the drug met primary and key secondary endpoints at week 24. Final approval now rests with the European Commission, which is expected to decide in the coming months.
Sign in to access this content
Sign InThe news comes amid a rapidly growing market for alopecia areata treatments, with new targeted therapies emerging. AbbVie's stock traded at $251.52 (close on June 26, 2026), within a range of $244.66–$253.35 in the last session. RINVOQ is already approved in the US and Europe for multiple indications including rheumatoid arthritis and psoriasis, broadening its revenue base.
Investors are focused on the European Commission's final decision, which could expand the eligible patient population and boost RINVOQ sales. Markets are also awaiting AbbVie's second-quarter earnings for further clarity on the impact of potential new approvals. Any positive regulatory update could support the stock in the near term, especially amid sustained demand for chronic dermatology treatments.